Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
16 Dezember 2020 - 10:33PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
16 December 2020 18:15 GMT
Transaction by Person Discharging Managerial
Responsibilities
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announced that, on 16 December
2020, it was notified of transactions in the Company's
Ordinary Shares of $0.25 each by certain Persons Discharging
Managerial Responsibilities (PDMRs) of the Company as set out
below.
PDMR
|
Position
|
Nature of the transaction
|
Quantity
|
Price
|
Philip Broadley
|
Non-Executive Director
|
Purchase of Ordinary Shares
|
1,310
|
GB£76.25
|
Nazneen Rahman
|
Non-Executive Director
|
Purchase of Ordinary Shares
|
259
|
GB£76.78
|
Nazneen Rahman
|
Non-Executive Director
|
Purchase of Ordinary Shares
|
258
|
GB£76.79
|
The attached notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further
detail.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Philip
Broadley
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Non-Executive
Director
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Purchase of AstraZeneca PLC Ordinary Shares
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
GB£76.25
|
1,310
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
16
December 2020
|
f)
|
Place of the transaction
|
XLON
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Nazneen
Rahman
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Non-Executive
Director
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Purchase of AstraZeneca PLC Ordinary Shares
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
GB£76.776
|
259
|
|
|
GB£76.791
|
258
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
517
GB£76.784
|
e)
|
Date of the transaction
|
16
December 2020
|
f)
|
Place of the transaction
|
XLON
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
16 December
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024